Vascular Inflammation Drives Cancer Spread Through Three Key Pathways
New research reveals how oral bacteria, oxidized cholesterol, and chemotherapy trigger vascular inflammation that fuels cancer metastasis.
Summary
A review from Hokkaido University examines how vascular inflammation in tumor blood vessels accelerates cancer progression and metastasis. Three key triggers are identified: Streptococcus mutans (an oral bacterium) activating endothelial cells, the oxLDL/LOX-1 metabolic signaling axis, and chemotherapy-induced vascular dysfunction. Together, these mechanisms help tumors establish pre-metastatic niches and evade immune surveillance. Promising countermeasures include microbiota modulation, metabolic targeting, and low-dose metronomic chemotherapy, all of which may preserve vascular integrity. The authors argue that targeting vascular inflammation represents a novel therapeutic strategy to simultaneously suppress metastasis and reduce cardiovascular risk in cancer patients.
Detailed Summary
Cancer metastasis remains one of the leading causes of cancer-related death, and emerging evidence points to vascular inflammation as a critical enabler of this process. When blood vessels within and around tumors become inflamed, they upregulate adhesion molecules and cytokines that help tumor cells attach, migrate, and escape immune detection — making the vascular environment a compelling therapeutic target.
This review from Hokkaido University synthesizes current knowledge around three distinct but converging triggers of tumor vascular inflammation. First, Streptococcus mutans — a bacterium classically associated with dental caries — can enter the bloodstream and activate tumor endothelial cells (TECs), promoting adhesion and inflammatory signaling. This finding draws an unexpected but important link between oral health and systemic cancer biology.
Second, the oxLDL/LOX-1 axis connects metabolic dysfunction, particularly oxidized low-density lipoprotein, to endothelial activation in the tumor microenvironment. This pathway bridges cardiovascular disease biology with oncology, suggesting that metabolic risk factors may worsen cancer outcomes through vascular mechanisms.
Third, conventional chemotherapy itself can paradoxically induce vascular dysfunction, potentially creating conditions that favor metastasis. Low-dose metronomic (LDM) chemotherapy is highlighted as a strategy that may preserve vascular integrity while maintaining anti-tumor activity.
The authors propose that targeting these inflammatory pathways — through microbiota modulation, metabolic interventions, or refined chemotherapy dosing — could suppress metastasis and reduce cardiovascular complications in cancer patients. However, the review is based on preclinical data, and validated biomarkers for clinical translation are still lacking. Rigorous human trials will be needed before these strategies can be widely adopted.
Key Findings
- Streptococcus mutans activates tumor endothelial cells, linking oral microbiome health to cancer metastasis risk.
- The oxLDL/LOX-1 signaling axis connects metabolic dysfunction to pro-inflammatory vascular changes in tumors.
- Conventional chemotherapy can paradoxically induce vascular dysfunction, potentially facilitating pre-metastatic niche formation.
- Low-dose metronomic chemotherapy shows preclinical promise for preserving vascular integrity and reducing inflammation.
- Targeting vascular inflammation may simultaneously suppress metastasis and lower cardiovascular risk in cancer patients.
Methodology
This is a narrative review article, not an original clinical or experimental study. The authors synthesize preclinical and mechanistic research on vascular inflammation in cancer. No new patient data or experimental results are presented.
Study Limitations
The review relies primarily on preclinical evidence, and clinical validation of the proposed mechanisms and therapeutic strategies is still lacking. Predictive biomarkers for patient selection have not yet been identified or validated. The scope is limited to three inflammatory triggers, and other vascular inflammatory pathways in cancer are not addressed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.